Keytruda Plus Chemotherapy Extends Survival in NSCLC Patients Lacking PD-L1 Expression

Sep 10, 2019

|

NEW YORK -- Pooled analysis from three studies suggests there may be a survival advantage for advanced non-small cell lung cancer patients who lack PD-L1 expression and receive pembrolizumab (Merck's Keytruda) and chemotherapy as a front-line option.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Keytruda Plus Chemotherapy Extends Survival in NSCLC Patients Lacking PD-L1 Expression

To read the full story....

Breaking News

Colorectal Cancer Patients Benefit from Biomarker-Guided Treatments in TAPUR Study

Myriad Genetics Seeks Supplemental Approval of HRD Test as CDx for GSK Ovarian Cancer Drug

UK's NICE Will Not Recommend Osimertinib for Untreated Non-Small Cell Lung Cancer

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

T Cell Assessment in Primary Melanomas Can Help Predict Metastatic Recurrence

Genetic Testing Challenges in Oncology: Patient Told Genetic Test was Negative Turns out to be MAP Carrier

Featured White Papers

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

What's Popular?

Myriad Genetics Seeks Supplemental Approval of HRD Test as CDx for GSK Ovarian Cancer Drug

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test

Colorectal Cancer Patients Benefit from Biomarker-Guided Treatments in TAPUR Study

Viral Cancer Early Detection Efforts Making Progress Toward the Clinic

Sponsorships